NCT00453362 - A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

April 30, 2010

Study Completion Date

April 23, 2010

Conditions

Non-Small Cell Lung Cancer

Interventions

OTHER

2-deoxy-2-[18F]fluoro-D-glucose (FDG)

FDG prepared in sterile buffered solution for intravenous injection. Dosage was based on the participant's weight not to exceed 15 mCi (millicurie).

OTHER

3'-deoxy-3'-[18F]fluorothymidine (FLT)

FLT 7 mCi dose prepared in sterile buffered solution for intravenous injection.

DRUG

erlotinib HCl

Tablets taken orally 150 mg/day.